ArticleScience translational medicine2012
Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.
Article in Science translational medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 185 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
185 citing papers in PubMed, 2 syntheses or guidelines pooled it, 363 citations in OpenAlex.
- Harnessing the immune system in the treatment of cutaneous T cell lymphomas.Frontiers in oncology · 2022Pooled it
- Tissue-Resident Memory T Cells in Skin Diseases: A Systematic Review.International journal of molecular sciences · 2021Pooled it
- Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease.The Journal of clinical investigation · 2020Trial
- Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2019Trial
- Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia.Science translational medicine · 2015Trial
- Cross-reactive tissue-resident memory T lymphocytes-concepts, evidence, and open questions.Journal of translational medicine · 2026Review
- Human epidermal resident memory T cells: beyond the dermal perspective.Frontiers in immunology · 2026Review
- Tissue-resident memory T cells in atopic dermatitis: mechanisms of residual inflammation, relapse, and therapeutic persistence.Frontiers in immunology · 2026Review
- Tissue-Resident Memory T Cells: Pioneering New Avenues in Cancer Immunotherapy.Cancer medicine · 2025Review
- Successfully maintained complete remission of mycosis fungoides by umbilical cord blood transplantation: a case report and literature review.Dermatology reports · 2025Article
- VEGFR2 blockade converts thermally ablative focused ultrasound into a potent driver of T cell-dependent anti-tumor immunity.bioRxiv : the preprint server for biology · 2025Article
- Cytokine and metabolite networks shape T cell residency and functionality at the term human maternal-fetal interface.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- IL-4 impairs the formation of skin-resident memory CD8Nature immunology · 2025Article
- Article
- Cutaneous T cell immunity.Nature immunology · 2025Review
- Tissue-Resident CD8+ T Cells as Mediators of Protective Immunity in Breast Milk Transmission of Human Cytomegalovirus.The Journal of infectious diseases · 2025Article
- Optimization of Immunotherapy Strategies Based on Spatiotemporal Heterogeneity of Tumour-Associated Tissue-Resident Memory T Cells.Immunology · 2025Review
- Bacterial vaginosis associates with dysfunctional T cells and altered soluble immune factors in the cervicovaginal tract.The Journal of clinical investigation · 2025Observational
- Long-term outcomes and clinical phenotypes associated with best response to low dose alemtuzumab in cutaneous T-cell lymphoma.Blood cancer journal · 2025Article
- Systemic Targeted Therapies in Patients with Relapsed/Refractory Advanced Stage Cutaneous T-cell Lymphoma: A Real-world Single-centre Case Series.Acta dermato-venereologica · 2025Article
125 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
Cutaneous T cell lymphoma (CTCL) is a cancer of skin-homing T cells with variants that include leukemic CTCL (L-CTCL), a malignancy of central memory T cells (T(CM)), and mycosis fungoides (MF), a malignancy of skin resident effector memory T cells (T(EM)). We report that low-dose alemtuzumab (αCD52) effectively treated patients with refractory L-CTCL but not MF. Alemtuzumab depleted all T cells in blood and depleted both benign and malignant T(CM) from skin, but a diverse population of skin resident T(EM) remained in skin after therapy. T cell depletion with alemtuzumab required the presence of neutrophils, a cell type frequent in blood but rare in normal skin. These data suggest that T(CM) were depleted because they recirculate between the blood and the skin, whereas skin resident T(EM) were spared because they are sessile and non-recirculating. After alemtuzumab treatment, skin T cells produced lower amounts of interleukin-4 and higher amounts of interferon-γ. Moreover, there was a marked lack of infections in alemtuzumab-treated L-CTCL patients despite the complete absence of T cells in the blood, suggesting that skin resident T(EM) can protect the skin from pathogens even in the absence of T cell recruitment from the circulation. Together, these data suggest that alemtuzumab may treat refractory L-CTCL without severely compromising the immune response to infection by depleting circulating T(CM) but sparing the skin resident T(EM) that provide local immune protection of the skin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.